Sessions highlighted the technology’s impact on eye care.
The drugmaker plans to market its own ophthalmic products rather than license them to others.
The company is developing Juvene, an accommodating IOL.
Government’s case hinged on timing of phone calls and trades rather than evidence of what was said.
The company acquired the Oculeve technology in 2015.
Device provides 1.5 million pulses per minute.
The move completes LENSAR’s financial restructuring after separating from Alphaeon.
The VEGF inhibitor is the first to gain this indication in the US market.
The lens will be commercially launched in October 2017 at the annual conference of the ESCRS.
Despite ongoing debate, surgeons continue to adopt technology.
Speakers also discussed next-generation accommodating and component IOLs.
The meeting focused on choosing the best surgical treatment from the growing number of options.
Firms in late-stage development include Sun Pharma and Kala Pharmaceuticals.
The Zeiss booth was a popular destination, with many surgeons test driving VisuMax systems.
Phase I/II data for Encore Vision’s eye drop showed promise.
Michael Ackermann, PhD, helped develop the dry eye neurostimulator purchased by Allergan and renamed TrueTear.
The drawing was held May 8 at the exhibit hall.
More than 31 million IOLs will be implanted by 2022, as industry becomes increasingly complex.
Revenues in the segment are expected to grow 4.4 percent over the next five years.
Novartis plans to release the results of its strategic review of Alcon toward the end of 2017.
The dry eye treatment continues to increase sales volume, despite the successful market entry of Shire’s Xiidra.
Valeant’s eye care segment now accounts for more than half of total company revenues.
Its portfolio companies include IanTech, Mynosys, SightLife Surgical, and RxSight.
The device is now available in the UK, Germany, Italy, and Spain.
The US Senate voted 57 to 42 to confirm Gottlieb as FDA commissioner on May 9.
Melgen was taken into custody immediately and awaits sentencing July 14.
You are not currently logged in.
©2018 Market Scope
Lost your Password